Aprea announces continuation of clinical Phase I/II-study of APR-246 in patients with leukemia
STOCKHOLM - December 12, 2011. Aprea AB today announces that the first patient has been dosed in a clinical Phase I/II-study of APR-246. The primary aim of the study is to evaluate safety and pharmacokinetics, but also to make an early assessment of effectiveness. Aprea is a Karolinska Development AB (publ) portfolio company. Other main owners are Industrifonden, Östersjöstiftelsen and Praktikerinvest. "This Phase I/II-study is a continuation of an earlier completed dose finding study, which showed that APR-246 was safe at predicted therapeutic plasma levels. The previous study also